Trasylol

Source: www.prweb.com --- 4 days ago
The FDA ordered Bayer to remove Trasylol (aprotinin) from the market after studies linked Trasylol to tens of thousands of deaths. A study looked at more than 78,000 patients from January 2003 to January 2006 and concluded that Trasylol users have a 64% higher death risk than those that took an alternative drug. The increased death risk was due to Trasylol dangerous side effects including kidney failure, heart attack, and stroke. ConsumerInjuryLawyers.com provides detailed information, helpful links and the CBS 60 Minutes Video Segment about Trasylol. (PRWeb Oct 2, 2008) Read the full story at http://www.prweb.com/releases/Trasylol/lawyers/prweb1407314.htm ...

Source: www.madisonrecord.com --- 6 days ago
Two Illinois citizens have filed suit against Bayer, seeking more than $2 million and claiming a drug the company produced caused acute renal failure and led to the death of one of the complainant's spouses. Both Gary Harms and Richard Kopsie were given the drug Trasylol during a coronary artery bypass graft surgery, according to the complaints filed Sept. 25 in St. Clair County Circuit Court. The drug was approved by the Food and Drug Administration in 1993 for use in patients undergoing the same surgeries as Harms and Kopsie and those who are at an increased risk for blood loss, the suit states. Harms underwent the surgery in which he was given the drug in 2005 at Des Peres Hospital in St. Louis, while Kopsie had his in August 1996 at Christian Hospital in St. Louis, the suit states. The drug caused damage to both Harms's and Kopsie's kidneys, resulting in acute renal failure, Harms and Linda Kopsie claim. Seth Sharrock Webb of Brown & Crouppen in St. Louis is representing the plaintiffs. Dialysis is a mandatory treatment when patients suffer from acute renal failure, according to the complaint. "It is a life support treatment," the suit states. "When healthy, the kidneys remove waste products from the blood and also remove excess fluid in the form of urine. Dialysis treatments have to duplicate both of these functions as dialysis and ultrafiltration." Bayer issued no warnings until Dec. 15, 2006, on the increased risk of kidne ...

Source: www.primenewswire.com --- 12 days ago
NEW YORK, Sept. 25, 2008 (GLOBE NEWSWIRE) -- In the wake of Bayer's announcement that it pulled its controversial heart surgery drug Trasylol from the market after a Canadian study suggested that its use increased surgical complications and death rates, nationally known plaintiff's advocates Napoli Bern Ripka & Associates, LLP has filed another lawsuit seeking damages on behalf of a heart surgery patient who, after being administered Trasylol (Aprotonin), experienced renal failure requiring dialysis treatment. ...

Source: blog.ennislaw.com --- 19 days ago
-Best Syndication News 08/30/2008- Acute Kidney Failure, also known as renal failure, entails the abrupt loss of the use of the kidneys to excrete waste and urine. Some of the causes of acute kidney failure are infections of the kidney, obstruction of the kidney track, decreased blood flow, and other disorders that cause clotting within the kidneys blood vessels. Symptoms of acute kidney failure include either a stoppage of urine or an increased amount of urine, swelling, fatigue, nausea and vomiting, and abrupt changes in mood. Once you are diagnosed with acute kidney failure, the amount of liquid you consume must be monitored and in most cases severely limited to the amount of urine that you are comfortably able to produce. In recent years, many cases of acute kidney failure have been linked to the drug Trasylol. Trasylol, manufactured by Bayer Pharmaceuticals, was predominantly used in open heart surgeries to control the amount of blood. Controlling the amount of blood in an open heart surgery is crucial because a bloodless heart is needed to be able for the doctors to be able to perform the surgery. Also, in an open heart surgery blood and oxygen is also supplied to the lungs and brain so that the body is able to function properly. You may be wondering why I am talking about open heart surgeries and acute kidney failure in the same sentence. It is because when blood needs to be controlled during an open heart surgery, it is done b ...

Source: www.prnewsnow.com --- 2 days ago
(Cardiology News and Information) Bernstein Liebhard Lifshitz LLP a law firm named to the prestigious National Law Journals Plaintiffs Hot List for the past five years announced today that it has added content to its Consumer Resource Center website that provides consumers with information about an FDA recall of Trasylol Consumer Injury Lawyers Trasylol Aprotinin Dangerous Drug Side Effects Information httpwwwconsumerinjurylawyerscomdangerousdrugstrasylolhtml...... ...

Source: www.topix.com --- 10 days ago
In the wake of Bayer's announcement that it pulled its controversial heart surgery drug Trasylol from the market after a Canadian study suggested that its use increased surgical complications and death rates, ... ...

Source: www.melosegno.com --- 18 days ago
On November 5, 2007, the FDA forced Bayer to suspend marketing of Trasylol. At a press conference that day, the FDA stated that it could not identif ...

Source: www.trasylollawblog.com --- 12 days ago
Bayer is preparing to defend Trasylol lawsuits from around the United States that could number in the thousands as the public becomes more aware of the devastating side effects of this heart surgery medication. Trasylol claims brought on behalf of individuals and families of heart surgery patients throughout the United States have been filed against the drug giant Bayer. Currently Trasylol lawsuits are being filed by individuals and families throughout the United States. No Trasylol class actions have been filed, however given the number of potential Trasylol victims, attorneys and courts will likely look to multidistrict litigation and class actions to more efficiently handle the growing number of cases. Bayer's growing Trasylol problems follow increasing reports of the drug's side effects. Trasylol has recently been linked to a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved by the Federal Drug Administration. Aprotinin is manufactured by Bayer under the brand name Trasylol. Until it was recently withdrawn from the market, Trasylol sales continued to increase even though studies indicated serious Trasylol kidney damage side effects. The FDA began a closer examination of the safety of Trasylol in January 2006 after the publication of studies linking the drug to dangerous side effects including heart attacks, kidney p ...

Source: www.trasylollawblog.com --- 31 days ago
One of the biggest questions people have when they or a family member have suffered side effects such as kidney failure , stroke or a heart attack following open heart surgery is how to find out whether or not Trasylol was used during the surgery. Patients who underwent bypass surgery most often do not know what medications were used during the surgery because their surgeon made the decision of whether to use Trasylol based on the risk of excessive blood loss during the procedure. Looking at the hospital records associated with the surgery is the best place to find out whether Trasylol was used. Alternatively, you can also look at the hospital billing statement to see if Trasylol (also referred to as “Aprotinin”) is listed under the charges. Under federal law called the “HIPAA Privacy Rule” you have the right to see and receive a copy of your medical records. Typically after requesting your medical records you should receive them within 30 days of the time of request. Common Questions: Q: Is there a charge for requesting my medical records? A: The hospital or medical provider is able under the law to charge a fee for retrieving and copying the requested medical records. Because of this, it is important to initially request only a limited number of surgery records to help lessen the charges associated with the request. In some situations the records can number into several hundred or thousands of pages depending on the specific circumst ...

Source: www.ncbi.nlm.nih.gov --- 7 days ago
Related Articles Aprotinin in pediatric neuromuscular scoliosis surgery. Eur Spine J. 2008 Sep 27; Authors: Kasimian S, Skaggs DL, Sankar WN, Farlo J, Goodarzi M, Tolo VT Reduction of blood transfusions in patients with neuromuscular scoliosis can decrease potential complications such as immune suppression, infection, hemolytic reaction and viral transmission. Aprotinin (Trasylol((R)), Bayer), an antifibrinolytic, has proven to be effective in reducing blood loss in cardiac and liver surgery, but little data exists in patients undergoing spinal fusion for neuromuscular scoliosis. The purpose of this study was to evaluate the safety and efficacy of aprotinin in pediatric neuromuscular scoliosis patients undergoing spinal fusion. The medical records of all patients undergoing initial spinal fusions for neuromuscular scoliosis between January 1999 and March 2003 were reviewed to determine demographic data, perioperative data, wound drainage and number of transfusion required. Cases were compared to a matched group of historical controls. We had 14 patients in the aprotinin group and 17 in the control group. Total blood loss in the aprotinin group was significantly lower compared to the control group (715 vs. 2,110 ml; P = 0.007). Significantly less blood loss occurred in the aprotinin group when blood loss per kilogram was evaluated as well (23 vs. 60 ml/kg, respectively; P = 0.002). Intra-operative packed red blood cell (PRBC) transfusi ...

Source: www.injuryboard.com --- 96 days ago
Preemption has been a hot topic throughout the pharmaceutical and legal fields for some time now and as we move closer to monumental decision from the Supreme Court on the issue it has become a real battlefield for both sides. The argument for preemption basically promotes the idea that FDA approval of a medication should preempt or prohibit individuals from filing lawsuits against the makers of the medication for injuries developed as a result of taking the medication. This line of arguing can only be considered logical if you assume that FDA had all of the information that it needed at the time to determine that the medication is safe for public use. The recent recall of Bayer's anti-bleeding medication Trasylol , demonstrates that these assumptions are false. Aprotinin is a naturally-occurring enzyme produced by cows. It was first discovered in the 1930's, and brought to market under the name Trasylol by Bayer in 1959. Trasylol increases the rate at which blood clots, and Bayer sought FDA approval to use the drug during Coronary Artery Bypass Graft ( CABG, pronounced cabbage ) surgery to reduce blood loss and minimize the need for blood transfusion. Trasylol was approved by the FDA in 1993 and was removed from the market in 2007 after evidence showed that it was causing patients to suffer renal failure, have heart attacks and strokes, and even die shortly after being given the drug . The number of lives that were lost as a resu ...

Source: www.tortdeform.com --- 97 days ago
The crux of the argument that FDA approval of a drug should preempt state lawsuits over that drug is that it should be experts at the FDA who decide whether a drug is safe and what warnings that drug's label should carry.  Implicit in this argument are the assumptions that the FDA has access to the information it needs to make expert decisions and that it will make its decisions quickly when lives are at risk.  The Trasylol story proves these assumptions to be false. Aprotinin is a naturally-occurring enzyme produced by cows.  It was first discovered in the 1930's, and brought to market under the name Trasylol by Bayer in 1959.  Trasylol increases the rate at which blood clots, and Bayer sought FDA approval to use the drug during Coronary Artery Bypass Graft ( CABG, pronounced cabbage ) surgery to reduce blood loss and minimize the need for blood transfusion. The FDA mistakenly approved the usage of Trasylol in 1993, and it rescinded that approval in 2007 after mounting evidence showed the drug was causing patients to suffer from renal failure, have strokes and heart attacks, and even die within thirty days of using the drug.  The total number of lives lost to Trasylol will never be known, but at least one researcher has pegged the death toll at 1,000 lives per month during 2006/2007.  Bayer Ignored Evidence That Trasylol Caused Renal Failure Trasylol had been available in Germany (Bayer is a German company) since 1959, and a number of ...

Source: www.georgiainjurylawyerblog.com --- 64 days ago
On May 14, 2008, the manufacturer of Trasylol officially pulled all remaining supplies of the blood clotting drug from the market. This drug, manufactured by Bayer (AG) is typically used by surgeons to control bleeding during heart surgery. Unfortunately, in a major study published in the New England Journal of Medicine, it was reported that the use of this drug significantly raised the risk of death for patients who used this product as opposed to other similar products on the market. A study conducted by a Canadian group found that patients that had been given Trasylol had a fifty percent (50%) higher death rate than patients who were given alternative drugs. Bayer (AG) originally suspended the sales of this drug in November of 2007 under pressure from the Food and Drug Administration. Patients who were undergoing heart bypass, valve replacement or other cardiac procedures were more likely to die than others who had received competing blood clotting drugs available on the market. Most the deaths that have been reported have been due to either kidney failure, heart failure, heart attacks or strokes following the surgery. In short, it has been well established that this drug is associated with severe complications attendant to heart surgery including renal failure. What is most troubling about this product is that for years it appears that the manufacturer was aware that it was dangerous but nonetheless concealed these known dangers fr ...

Source: classactiondefense.jmbm.com --- 51 days ago
Judicial Panel Grants Defense Request for Pretrial Coordination of Class Action Lawsuits Pursuant to 28 U.S.C. § 1407, Unopposed by Certain Class Action Plaintiffs but Opposed by Others, but Concludes Class Actions should be Transferred to Southern District of Florida Eighteen class actions were filed in 14 different federal district courts against various defendants, including Bayer Corp., Bayer Healthcare Pharmaceuticals, Bayer Healthcare, LLC, Bayer AG, and Bayer Healthcare AG (collectively “Bayer”), alleging product liability claims based on the safety of the Bayer drug Trasylol. In re Trasylol Products Liab. Litig. , ___ F.Supp.2d ___ (Jud.Pan.Mult.Lit. April 7, 2008) [Slip Opn., at 1]. Additionally, another 18 class action lawsuits had been filed and were treated as tag-along cases by the court. Id. , at 1 n.2. Defense attorneys for Bayer filed a motion with the Judicial Panel for Multidistrict Litigation (MDL) requesting centralization of the class actions pursuant to 28 U.S.C. § 1407 in the District of Connecticut or, alternatively, the Northern District of Georgia. Id. , at 1. Plaintiffs in 6 of the class actions before the court and in 2 of the potential tag-along cases supported pre-trial coordination, but argued for various other districts as the appropriate transferee court; plaintiffs in 4 of the class actions before the court an in one of the potential tag-along cases opposed centralization. Id. The Judicial Panel grante ...

Source: tulsa.injuryboard.com --- 94 days ago
Bayer HealthCare Pharmaceuticals has notified the FDA that the company has begun removal of remaining Trasylol from the U.S. market, which includes mostly hospitals, warehouse or physician's stock. Bayer and the FDA are working together to ensure a smooth transition. Under a limited use agreement, Trayslol is limited to investigational use of the drug according to the procedures outlined in a special treatment protocol which allows for certain patients who are at increased risk of blood loss during coronary artery bypass graft surgery and have no other alternative therapy options. Doctors who use this option must also verify that the benefits clearly outweigh the risk to their patient. The FDA limits access to certain drugs, such as Trasylol, to patients with serious or life threatening disease or conditions who lack other medical options who may benefit from such therapies. This type of access requires the submission of protocol which is then reviewed and approved by the agency. Bayer has agreed to provide Traysylol the limited use above. Trasylol Background: On November 5, 2007 the U.S. Food and Drug Administration announced that Bayer agreed to an FDA-requested marketing suspension of Trasylol, a drug to control bleeding during heart procedures. At that time, preliminary results from a Canadian study suggested increased risk of death compared to two other drugs used for the same purpose included in the study. Originally posted at Inj ...

Source: www.blurpalicious.com --- 65 days ago
Trasylol class action information. Bayer (Aprotinin) Trasylol kidney failure, heart attack and stroke side effects. The latest news from Trasylol att 4 Vote(s) ...

Source: www.medworm.com --- 12 days ago
MIAMI - Bayer Corp. is objecting to a proposal that it report all settlements, including ones involving nonmultidistrict litigation claims, to plaintiffs in the Trasylol MDL (In Re: Trasylol Products Liability Litigation, MDL Docket No. 1928, No. 08-md-1928, S.D. Fla.). Full story on lexis.com (Source: LexisNexis® Mealey's™ Emerging Drugs & Devices Legal News)   MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed. ...

Source: www.texaslawyers.com --- 92 days ago
Evidence has shown that the heart surgery drug, Trasylol, can cause significant health problems including kidney failure resulting in death or the need for dialysis. Unfortunately, even though there has been significant knowledge of these potential health problems those profiting from the sale of Trasylol were slow to pull the drug off the market potentially causing thousands of deaths and kidney damage in tens of thousands of heart patients. Texas Trasylol Lawyer (Texas Trayslol Lawsuits) Delays in pulling Trasylol from the market and publicizing the known and suspected health risk of Trasylol may have caused thousand of unnecessary deaths as well as caused many heart surgery recipients to suffer unnecessary kidney failure damage. Because of the large number of people this drug may have hurt or killed, several Trasylol Lawyers are investigating potential Trasylol lawsuits including when the manufacturer first learned of potential health risks of the drug and if anyone intentionally concealed these health risks. Further, several Trasylol lawyers are investigating if these same corporations and people may have over stated the benefits of Trasylol in order to maximize profits. It is estimated that the annual projected sales of Trasylol was over $600 million producing huge profits for those that had a duty to disclose any know health hazards with the drug. Texas Trasylol Attorney Jason Coomer is working with several lawyers throughout Texas ...

Source: www.trasylollawblog.com --- 48 days ago
As more Trasylol lawsuits are filed there is increasing pressure to revisit individuals right to hold companies accountable when they market a dangerous product. On the same day of a House Oversight hearing the New England Journal of Medicine (NEJM) published the results of a Canadian study that showed Trasylol (Aprotinin) increased the risk of death in patients by 50 percent. Previous studies had associated Trasylol with kidney failure, heart attacks and stroke. On May 14, 2008 Gegory Curman, the executive editor of the NEJM testified regarding safety issues with drugs following their approval. Henry Waxman, D-CA, the House Government Reform and Oversight Committee Chair gave the opening statements.  TESTIMONY House Committee on Oversight and Investigations Wednesday, May 14, 2008 Preemption – Drugs and Medical Devices My name is Gregory Curfman, and I am the executive editor of the New England Journal of Medicine . I am here today along with my colleague, Dr. Stephen Morrissey, the managing editor, to provide testimony from our Journal. We will make the case that preemption of common-law tort actions against drug and medical device companies is ill advised and will result in less safe medical products for the American people. The New England Journal of Medicine is nearly 200 years old. Our mission is to publish important advances in medical research, including research on new drugs and medical devices. During my 23 years at the New ...